NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ:OCUL) between March 10, 2016 and July 11, 2017. You are hereby notified that Levi & Korsinsky filed Kim v. Ocular Therapeutix, Inc., a securities class action lawsuit in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-sba/ocular-therapeutix-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Ocular Therapeutix you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Tesla Launches New Model Y Variant in the US Starting at $41,990
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 



